Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01826877 · ClinicalTrials.gov registry record · Phase 1
Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer
A Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01826877 is a Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 12 participants, below the 203-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01826877, a Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best dose of autologous dendritic cells in treating patients with metastatic kidney cancer. Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL therapeutic autologous dendritic cells
- BIOLOGICAL AdGMCAIX-transduced autologous dendritic cells
Study Locations (1)
California
- Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-01-14 |
| Est. Completion | 2021-05-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01826877
The ClinicalTrials.gov registry entry for NCT01826877 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 203-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (94% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01826877 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01826877 about?
NCT01826877 is a clinical study titled "Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer". This phase I trial studies the side effects and best dose of autologous dendritic cells in treating patients with metastatic kidney cancer. Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells.
What is the current status of trial NCT01826877?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2013-01-14. Estimated completion is 2021-05-27.
What conditions does trial NCT01826877 study?
This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer.
What interventions are being tested in trial NCT01826877?
The interventions under investigation include: laboratory biomarker analysis (OTHER), therapeutic autologous dendritic cells (BIOLOGICAL), AdGMCAIX-transduced autologous dendritic cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01826877?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01826877 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clear Cell Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RECRUITING · Phase 1
-
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
RECRUITING · Phase 1
-
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
RECRUITING · Phase 1
Explore more on PlainTrial
Clear Cell Renal Cell Carcinoma
All registered trials for this condition
Stage IV Renal Cell Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.